AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06790368 — intervention group
Intervention type: BIOLOGICAL
Intervention: VENOX
Description: Treatment with allergy vaccine against Vespula spp. (wasp) or Apis mellifera (bee), as per clinical indication.
Study NCT06791824 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CM313(SC) injection
Description: Phase IB: CM313(SC) administered at low dose according to the protocol. Phase II: CM313(SC) administered at different doses based on Phase IB's results.
Study NCT06791824 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CM313(SC) injection
Description: Phase IB: CM313(SC) administered at medium dose according to the protocol. Phase II: CM313(SC) administered at different doses based on Phase IB's results.
Study NCT06791824 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CM313(SC) injection
Description: Phase IB: CM313(SC) administered at high dose according to the protocol. Phase II: CM313(SC) administered at different doses based on Phase IB's results.
Study NCT06790628 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fibula free flap
Description: surgical technique used in reconstructive surgery where a segment of the fibula bone, along with its blood vessels, is taken from the lower leg and transplanted to reconstruct defects in the mandible due to its length, strength, and ability to support dental implants.~The blood vessels are connected to nearby vessels at the reconstruction site to ensure the bone's survival and integration.~The procedure is highly versatile and often referred to as the gold standard for mandibular reconstruction.
Study NCT06791447 — intervention group
Intervention type: OTHER
Intervention: AI-assisted Predictive Model for Dialysis Outcomes
Description: This study utilizes an AI-assisted predictive model that analyzes multimodal data from electronic health records, including medical history, laboratory results, dialysis treatment details, and clinical observations, to predict outcomes for dialysis patients. The model employs deep learning algorithms to predict mortality risk, intermediate outcomes such as anemia, blood pressure control, nutrition, and calcium-phosphate metabolism, and helps identify early signs of deterioration. The intervention is not a direct treatment or procedure but aims to develop a tool for predicting patient outcomes and optimizing treatment strategies to improve overall health and survival rates for dialysis patients.
Study NCT06156189 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Enteral Feeding
Description: Feeding via Nasogastric tube in intubated and ventilated patients
Study NCT04877886 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ultrasound with IV contrast
Description: To compare the efficiency over the ultrasound scan within contrast
Study NCT04877886 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: CT with IV contrast
Description: CT with IV contrast
Study NCT04877886 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound without IV contrast
Description: Ultrasound without IV contrast
Study NCT04877886 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: CT without IV contrast
Description: CT without IV contrast
Study NCT06791772 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CM313 injection
Description: CM313 600mg（4ml）/vial. Subcutaneous injection 600mg. The first 5 doses were administered weekly, followed by every two weeks, a total of 14 doses.
Study NCT06791772 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CM313 injection
Description: CM313 600mg（4ml）/vial. Subcutaneous injection 1200mg. The first 5 doses were administered weekly, followed by every two weeks, a total of 14 doses.
Study NCT06791772 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 4 mL/vial. Subcutaneous injection 4 or 8 mL. The first 5 doses were administered weekly, followed by every two weeks, a total of 14 doses.
Study NCT05385965 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meaning-Centered Pain Coping Skills Training
Description: The goal of this intervention is to help participants reduce pain interference so that they can engage with what gives them a sense of meaning, purpose, and peace.
Study NCT06789757 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine Hydrochloride
Description: Memantine (5mg) is an N-methyl-D-aspartate (NMDA) receptor antagonist given in 21-day cycles over six months in combination with Bevacizumab and Atezolizumab. Each week memantine will be escalated by 5mg as tolerated
Study NCT06789757 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab (15mg/kg) is a vascular endothelial growth factor inhibitor given in 21-day cycles over six months in combination with Memantine and Atezolizumab.
Study NCT06789757 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab (1200mg) is a programmed death-ligand 1 (PD-L1) blocking antibody given in 21-day cycles over six months in combination with Memantine and Bevacizumab
Study NCT06279559 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music-therapy
Description: 10 sessions of online music therapy held by expert music therapists
Study NCT05787470 — intervention group
Intervention type: BEHAVIORAL
Intervention: Quantative sensory testing
Description: All participants will undergo quantitative sensory testing for assessment of endogenous pain modulation using painful heat, mechanical, and cold stimuli in a laboratory session lasting approximately 1 hour.
Study NCT04807101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midazolam alone
Description: elimination of fentanyl from conscious sedation
Study NCT05041205 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beauty drink powder
Description: Beauty drink powder is designed as a oral beauty product to provide benefits to skin
Study NCT05041205 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Beauty drink powder
Description: Beauty drink powder is designed as a oral beauty product to provide benefits to skin
Study NCT05041205 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cosmetic apparatus
Description: This device is designed to let participants to experience brighter, softer, smoother skin and an energizing facial massage. A synergestic effect when combine with beauty drink powder is expected.
Study NCT05041205 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Cosmetic apparatus
Description: This device is designed to let participants to experience brighter, softer, smoother skin and an energizing facial massage. A synergestic effect when combine with beauty drink powder is expected.
Study NCT05045014 — intervention group
Intervention type: OTHER
Intervention: Balance assessment
Description: Romberg test and one-leg standing test will be used.
Study NCT05787470 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood Draw
Description: Sample of blood will be taken.
Study NCT04220931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: botulinum toxin injection
Description: injection of Botulinum toxin A 100 UI, single dose administration, in the major papilla, in the Oddi sphincter, during upper gastrointestinal endoscopy.
Study NCT06633718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meropenem and Pralurbactam
Description: 3g，q8h，120min infusion
Study NCT06633718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Description: 100mL，q8h，60min infusion
Study NCT06633718 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ceftazidime-avibactam
Description: 2.5g，q8h，120min infusion
Study NCT06633718 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole
Description: 0.915g，q8h，60min infusion
Study NCT05567120 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: PATH-Care
Description: Individuals will receive the 8-session PATH-Care intervention, delivered virtually (via videoconference or phone) to mitigate negative emotions and stress experienced by informal caregivers of individuals with ADRD. The therapist in the first session will also guide the participant in the tablet-based exercises (WELLPath).
Study NCT03451487 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Panadol®
Description: Acetaminophen 500mg Tablet
Study NCT04864470 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stroke Odysseys
Description: The participants will take part in a twelve-week performance programme that takes place online/in a community halls/arts centre. Sessions run for three hours and during these sessions, participants devise a dance and music performance work from their own stories. The culmination of the programme will be a public facing performance to an audience of carers, health care practitioners, friends, family and the wider community, done online through Zoom.~After the performance is completed, participants will be invited to a training programme where they learn to act as advocates for life after stroke - termed 'stroke ambassadors'. The training will be a four-day programme. The programme will take place once weekly and is led by a team of artists supported by a leadership coach, on Zoom.~Following training, ambassadors will support artists in recruitment, befriend the newly discharged stroke survivors and take part in small scale performance tours to challenge the perception of disability.
Study NCT05182255 — intervention group
Intervention type: DEVICE
Intervention: Evolution® Esophageal Stent Systems, Europe: Fully and Partially Covered
Description: To aid in maintaining patency of the esophagus in cases of obstruction of the esophagus caused by an esophageal disease and to seal tracheoesophageal fistula.
Study NCT03451487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SafeTynadol®
Description: Acetaminophen 500mg Tablet
Study NCT05316883 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Clozapine
Description: clinical doses adjusted to sideeffects and clinical effect
Study NCT05131243 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chemotherapy time
Description: 6 months of chemotherapy
Study NCT05131243 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy time
Description: 3 months of chemotherapy
Study NCT05045014 — intervention group
Intervention type: OTHER
Intervention: Unterberger test
Description: During 50 steps, he will count in place with 45 degrees of hip flexion, and after 50 steps, the angle of rotation between the first position and the final position of the right foot will be measured with the help of a goniometer and the displacement distance.
Study NCT06379724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Description: 100mg/mL 10mL vials x2 of injectable tranexamic acid will be filled into a 20 milliliter syringe with a spray tip.
Study NCT06379724 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thrombin JMI
Description: The wound base is then sprayed with a film of Thrombin-JMI
Study NCT06379724 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: skin graft
Description: Skin is taken from uninjured part of the participant's body and used to surgically cover a wound or injured area with skin that contains the epidermis and a portion of the dermis.
Study NCT06379724 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: skin graft
Description: Skin is taken from uninjured part of the participant's body and used to surgically cover a wound or injured area with skin that contains the epidermis and a portion of the dermis.
Study NCT06197373 — intervention group
Intervention type: PROCEDURE
Intervention: Laparoscopic cholecystectomy
Description: Doing laparoscopic cholecystectomy after ERCP at different intervals
Study NCT05045014 — intervention group
Intervention type: OTHER
Intervention: Corsi Block Tapping (mobıl app)
Description: Spatial memory will be evaluated.
Study NCT05045014 — intervention group
Intervention type: OTHER
Intervention: Navigation performance
Description: Two triangles (one equilateral, one oblique triangle, at 30°, 60° and 90° angles respectively) with route segment lengths between 150 and 300 cm will be marked on the floor and the participants will be asked to complete the task with their eyes closed. The final deviation amount will be recorded.
Study NCT05045014 — intervention group
Intervention type: OTHER
Intervention: Cobb angle measurement
Description: It will be evaluated with the help of X-ray.
Study NCT05045014 — intervention group
Intervention type: OTHER
Intervention: Scolio Detector (mobıl app)
Description: The degree of rotation will be measured with the mobile application called Scolio Detector.
Study NCT05460390 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic drug monitoring (TDM)
Description: Serum trough level of adalimumab and anti-adalimumab antibody will be obtained at time of enrollment and every 3 months until the end of the study. Adalimumab dose optimization goal will be to achieve trough drug level in the range of 5 -8 μg/mL.
Study NCT06792032 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: peer mentoring with mobile application
Description: peer mentoring with mobile application
Study NCT06791785 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Before Application
Description: All groups will be asked to fill out forms before the application (Westside test anxiety scale, burdon attention test, descriptive information form)
Study NCT06201169 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: implant placement
Description: All patients received four implants in the lower arch
Study NCT06791785 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Before Application
Description: All groups will be asked to fill out forms before the application (Westside test anxiety scale, burdon attention test, descriptive information form)
Study NCT06791785 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Before the 1st Written Exam
Description: Fill out forms before the 1st written exam (Westside test anxiety scale, burdon attention test, descriptive information form)
Study NCT06201169 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: implant placement
Description: All patients received four implants in the lower arch
Study NCT06791785 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Before the 1st Written Exam
Description: Fill out forms before the 1st written exam (Westside test anxiety scale, burdon attention test, descriptive information form)
Study NCT06791785 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: End of Term
Description: Fill out forms at the end of the term (Westside test anxiety scale, burdon attention test, descriptive information form)
Study NCT06791785 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: End of Term
Description: Fill out forms at the end of the term (Westside test anxiety scale, burdon attention test, descriptive information form)
Study NCT06791356 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy for insomnia
Description: 8 sessions of therapy that focus on psychoeducation about sleep hygiene, cognitive restructuring of dysfunctional beliefs that reinforce insomnia, stimulus control to eliminate the association between the bed and wakefulness, sleep restriction in order to establish a consistent sleep schedule, and relaxation training to reduce anxiety that interferes with sleep
Study NCT06791356 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep hygiene education
Description: One session of education about behavioral strategies to optimize sleep quality
Study NCT05621408 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention Training Technique
Description: Attention Training Technique is a six weeks psychological intervention provided by trained professionals
Study NCT05983016 — intervention group
Intervention type: DEVICE
Intervention: Philips EPIQ-7, Philips Healthcare, Bothell, WA, USA
Description: All patients had their abdominal aortic aneurysm maximum anterior-posterior diameter estimated with two-dimensional ultrasound using a 5 MHz curved array transducer (Philips® C5-1 transducer, Philips Healthcare, Bothell, WA, USA).~After the acquisition, a three-dimensional ultrasound acquisition was performed with a 3D-matrix transducer (Philips® X6-1 transducers, Philips Healthcare, Bothell, WA, USA).
Study NCT04903886 — intervention group
Intervention type: OTHER
Intervention: observational
Description: observational
Study NCT05459207 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate Fat Meal
Description: A liquid meal consisting of powdered protein and complex carbohydrates blended with coconut oil and peanut butter in ratios required to achieve the desired calorie and macronutrient distributions of a normal/moderate fat meal.
Study NCT05459207 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Fat Meal
Description: A liquid meal consisting of powdered protein and complex carbohydrates blended with coconut oil and peanut butter in ratios required to achieve the desired calorie and macronutrient distributions of a high-fat meal.
Study NCT06190470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis
Description: Cannabis product is from the extraction of the powdered, dried and mature pistillate inflorescences of Cannabis sativa L. containing THC 30mg/ml.
Study NCT05668078 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Rapid Antigen Testing (RAT) for COVID-19
Description: COVID-19 RAT intervention done among the school students to see if RAT test can play a role in reducing absenteeism. School type-1-only for symptomatic participants, School type-2-Serial testing at three days interval for all participants and School type-3 got no testing.
Study NCT04768595 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two, 1g capsules taken daily with food
Study NCT04768595 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ceto 10
Description: Two, 1g capsules daily with food
Study NCT04768595 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fish oil
Description: Two, 1g capsules daily with food
Study NCT05575531 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MEWSS and Nursing Guide Application
Description: MEWSS and Nursing Guide application will be used for the patients in the experimental group. According to the Nursing Guide application, patients with MEWS above 4 will be monitored every 5 minutes, while those with a score below 4 will be monitored for 10 minutes. will be followed intermittently. Nursing interventions will be made in accordance with the problems experienced by patients with a score above 4.
Study NCT05076097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orelabrutinib in in combination of rituximab and lenalidomide(OLR)
Description: Induction treatment phase: Orelabrutinib: 150mg QD D1-28; Lenalidomide: Cycle 1: 15mg QD D1-21, if no dose-limiting toxicity occurred in Cycle 1, cycle 2-6: 20mg QD D1-21; Cycle 1: 375 mg/m2 d1, 8,15,22; Cycle 3, 5: 375 mg/m2 D1 Maintenance treatment phase: Orelabrutinib: 150mg QD D1-28; Lenalidomide: cycle 7-24: 15mg QD D1-21; Cycle 7, 9, 11, 13, 15, 17, 19, 21, 23: 375 mg/m2 D1. 28 days for a cycle.
Study NCT06190470 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is similar to Cannabis product but do not contain THC.
Study NCT05126511 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Application of CES via ear clips
Description: Use of 100µA CES for one hour per day over PR program
Study NCT05126511 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham: No application of CES via ear clips
Description: Use of Sham CES for one hour per day over PR programm
Study NCT06090812 — intervention group
Intervention type: OTHER
Intervention: Ultrasound evaluation
Description: Ultrasound evaluation of volume status, right heart function, and pulmonary edema.
Study NCT04753346 — intervention group
Intervention type: OTHER
Intervention: Physical Activity Level
Description: International Physical Activity Questionnaire
Study NCT04753346 — intervention group
Intervention type: OTHER
Intervention: Anxiety and Depression Assessment
Description: Hospital Anxiety and Depression Scale
Study NCT04753346 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Exercise Capacity
Description: 6 Minute Walk Test
Study NCT04753346 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Pulmonary Function Test
Description: Spirometry
Study NCT06070636 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bTAE-HAIC
Description: bTAE procedure was a 2.8-F microcatheter was superselectively inserted into the tumor feeding artery using the coaxial technique. Then blank microspheres were used according to the tumor blood supply vessels (40-120um, 100-300um, 300-500um, 500-700um). The microcatheter was reserved at the proper/left/right hepatic artery according tumor location. After the patient returned to the ward, the following FOLFOX-based regime was intra-arterially administered through the microcatheter. The FOLFOX regimen was administered via the hepatic artery as follows: 85 or 135 mg/m2 oxaliplatin from hour 0 to 2 on day 1, and 400 mg/m2 leucovorin from hour 2 to 4 on day 1, and 400 mg/m2 fluorouracil bolus at hour 5 on the day 1; and 2400 mg/m2 fluorouracil over 46 h on days 1 and 2.
Study NCT06070636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: 12 mg (or 8 mg) once daily (QD) oral dosing.
Study NCT06070636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: 200mg intravenously every 32 weeks
Study NCT05032664 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-based aromatherapy programme
Description: 1 hour individualised face-to-face training to family caregivers, and 3 weeks aromatherapy intervention delivered by family caregivers (aromatherapy inhalation 2 times per day, each for 1 hour, using 2 drops of Lavandula angustifolia essential oil.